|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
CHAIKIN MONEY FLOW
Trading: SELL @ $3.61
Signal Strength: MEDIUM
Opthea (ASX:OPT) current price has highlighted recent selling pressure and the continuation of a bearish trading conditions. Currently, the CMF is -0.02. OPT.AXThe bearish signal has been active for 0 day. During the quarter, the lowest CMF value was -0.24 occurring on the Jan 23 2020.
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading exit. Indicator can be applied to the short/medium term timeframe, but the best results are obtained with larger cyclical swings in-line with the trend direction. This accumulation / distribution oscillator can provide guidance on the money flow direction from the companies recent trading.
Developed by Marc Chaikin, Chaikin Money Flow measures the amount of Money Flow Volume over a specific period. Money Flow Volume forms the basis for the Accumulation Distribution Line. Instead of a cumulative total of Money Flow Volume, Chaikin Money Flow simply sums Money Flow Volume for a specific look-back period, typically 20 or 21 days. The resulting indicator fluctuates above/below the zero line just like an oscillator. Chartists weigh the balance of buying or selling pressure with the absolute level of Chaikin Money Flow. Chartists can also look for crosses above or below the zero line to identify changes on money flow.
Calculation: Chaikin Money Flow (20):
1) Money Flow Multiplier = [(Close - Low) - (High - Close)] / (High - Low);
2) Money Flow Volume = Money Flow Multiplier x Volume for the Period;
3) 20-period CMF = 20-period Sum of Money Flow Volume / 20 period Sum of Volume;
PROFILE: Opthea (OPT.AX)
Stock Exchange: ASX
Ticker Codes: | OPT.AX | ASX:OPT |
Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.
|MVP Medical Developments||10.28||8.8||674,204||-0.19||BEARISH|
|FBR Fastbrick Robotics||0.06||5.8||881,024||-0.52||BEARISH|
|NZK New Zealand King Salmon Investments||2.2||5.3||8,766||-0.1||BEARISH|
|MNS Milnes Holdings||0.11||4.8||239,846||-0.1||BEARISH|
|HFR Highfield Resources||0.8||4.6||86,664||-0.37||BEARISH|
|HUO Huon Aquaculture||4.7||4.4||14,880||-0.73||BEARISH|
|VRL Village Roadshow||4.02||4.4||636,398||-0.58||BEARISH|
|EOS Electro Optic Systems Holdings||9.85||3.9||490,421||-0.35||BEARISH|